Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Mirikizumab Injections in Healthy Subjects
NCT03456713Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2018
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mirikizumab in ulcerative colitis (UC), Crohn's disease and psoriasis (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration at Day 85, Area Under the Concentration Versus Time Curve From Time Zero to Infinity at Day 85 and 2 more. Started Mar 2018; status: completed.
02
Drugs
mirikizumab
03
Conditions
ulcerative colitis (UC)Crohn's diseasepsoriasis
Beyond the preview
Go deeper on NCT03456713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03456713.